The linked FDA record set links BTL Industries, Inc. to a single 510(k) clearance: K262353 for the device BTL-299-F. The filing is a Traditional premarket notification reviewed by the Gastroenterology, Urology panel, with a Summary statement and no third-party review. The applicant address on the filing is 362 Elm St., Marlborough, Massachusetts 01752, and the correspondence is addressed to David Chmel as CEO North America. That address is a filing contact location, not a verified corporate headquarters. [1][2][5]
The cleared device and its regulatory classification
BTL-299-F falls under regulation number 21 CFR 876.5320, described in the FDA letter as a Nonimplanted Electrical Continence Device, regulatory Class II, product code KPI. The openFDA classification name is Stimulator, Electrical, Non-Implantable, For Incontinence, with medical specialty listed as Gastroenterology, Urology. The decision code is SESE, meaning Substantially Equivalent, and the clearance type is Traditional. [1][2][5]
The stated intended use covers entirely non-invasive electromagnetic stimulation of pelvic floor musculature for rehabilitation of weak pelvic muscles and restoration of neuromuscular control in the treatment of male and female urinary incontinence. A separate passage in the same source also describes electromagnetic stimulation for treatment of fecal incontinence in male and female patients. [2][7][8]
Submission timeline and review path
The FDA cover letter dates the submission July 10, 2026, and records receipt the same day; the decision letter is dated September 23, 2026. The advisory committee and review advisory committee are both Gastroenterology, Urology, and the expedited review flag is blank in the openFDA record. [1][2]
The filing is identified as a Traditional 510(k) with a Summary rather than a statement, and the third-party flag is N. A summary excerpt states that, based on the technical information provided in the premarket notification, the BTL-299-F has been shown to be substantially equivalent to currently marketed predicate devices. [1][5][7]
What the collection does and does not show
The linked collection contains one 510(k) record, and its decision count is one SESE. The record sample likewise holds one entry, K262353, so the sample and the collection coincide here. These counts describe the supplied filings as of the snapshot date; they are not measures of total company sales, total portfolio breadth or safety performance. [1][5]
No recall records appear in the supplied set, and no other submission types are linked. Absence of additional filings in this collection does not establish that none exist. [1]
Applicant identity versus brand material
BTL Industries, Inc. is the applicant of record on K262353. Company-level descriptions appear only on BTL-published pages: btlnet.com states that BTL has been a global innovator in physiotherapy, cardiology and aesthetic medicine for over 30 years, and a BTL about page describes a global medical technology company with over 30 years of experience developing and manufacturing medical devices. [1][3][4]
A BTL innovation page lists segments including aesthetics, rehabilitation, mental health, cardiology, hospital-based therapies and veterinary medicine, and associates the EMSCULPT, EMSELLA and related EM-family trademarks with BTL Industries, Inc. Those pages do not establish a verified parent, ownership chain or corporate headquarters for the FDA applicant, and the relationship between the brand pages and the K262353 applicant is not documented in the public documents. [6]




